Stock market analyst Salil Sharma has maintained 'buy' rating on Biocon Ltd stock with a target of Rs 354

According to analyst, the interested investors can buy the stock with stop loss of Rs 340.

The stock of the company, on Sep 03, closed at Rs 345.50 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 356 and a low of Rs 230 on BSE.

Current EPS & P/E ratio stood at 15.62 and 22.22 respectively.

India's leading biotechnology firm Biocon Ltd has declared that it is making entry in the critical care section that eyes to offer up cure for hospital infections, which consists of post surgical problems and trauma.

Moreover, the company has established a novel comprehensive care segment in order to offer up reasonable solutions to hospital acquired infections.

As Biocon's fifth unit after oncology, nephrology, diabetology, and cardiology, the newly opened division will make use of five homegrown drugs for curing critical sicknesses including septicemia, nosocomial pneuomonia and other severe hospital infections.

Besides, the country's top biotech firm, Biocon Ltd, is ready to launch its derma or skincare range as it is looking forward to strengthen its portfolio of therapeutic sections in which it offers products.